口服塞利尼索选择性抑制核输出治疗复发或难治性多发性骨髓瘤
这项II期试验评估口服塞利尼索80 mg联合地塞米松20 mg(均每周两次)治疗对硼替佐米、卡非佐米、来那度胺和泊马度胺均难治的多发性骨髓瘤患者,总体缓解率为21%,四药难治与五药难治患者相似,高危细胞遗传学患者为35%。
要点
- 总体缓解率为21%,四药难治21%与五药难治20%相似。
- 高危细胞遗传学患者缓解率为35%(17例中6例)。
- 最常见≥3级不良事件为血小板减少(59%)和贫血(28%)。
核心结论
- 塞利尼索联合地塞米松在既往重度治疗、治疗选择有限的难治性骨髓瘤患者中总体缓解率为21%。
研究设计与样本
- II期试验,评估口服塞利尼索80 mg联合地塞米松20 mg、均每周两次给药。
- 纳入对硼替佐米、卡非佐米、来那度胺和泊马度胺难治的多发性骨髓瘤患者(四药难治),其中部分患者还对一种抗CD38抗体难治(五药难治)。
- 共79例患者,48例为四药难治,31例为五药难治;患者既往接受治疗的中位方案数为7。
- 主要终点为总体缓解率(ORR)。
主要发现
- 总体缓解率为21%,四药难治患者为21%,五药难治患者为20%。
- 高危细胞遗传学(包括t(4;14)、t(14;16)和del(17p))患者缓解率为35%(17例中6例)。
- 中位缓解持续时间为5个月,缓解患者中65%在12个月时存活。
- 最常见的≥3级不良事件为血小板减少(59%)、贫血(28%)、中性粒细胞减少(23%)、低钠血症(22%)、白细胞减少(15%)和疲乏(15%)。
- 因不良事件中断给药者41例(52%),减量者29例(37%),终止治疗者14例(18%)。
关键数值与推荐
- 塞利尼索80 mg与地塞米松20 mg均为口服、每周两次。
- 总体缓解率21%;四药难治21%,五药难治20%。
- 高危细胞遗传学患者缓解率35%(6/17)。
- 中位缓解持续时间5个月,缓解患者12个月存活比例65%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
引用
- Vogl DT, Dingli D, Cornell RF, et al. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018. PMID: 29381435. doi:10.1200/JCO.2017.75.5207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。